Journal of Clinical and Aesthetic Dermatology

AUG 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/870497

Contents of this Issue

Navigation

Page 54 of 67

55 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY august 2017 • volume 10 • number 8 r e v i e w for female patients with acne, hirsutism, or androgenic alopecia. Br K Dermatol. 1985;112:124–125. 45. goodfellow a, alaghband-Zadeh J, carter g, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–214. 46. Fritsch m, Orfanos ce, Zouboulis cc. sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 2001;116:793–800. 47. akamatsu H, Zouboulis cc, Orfanos ce. spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5alpha- dihydrotestosterone in vitro. J Invest Dermatol. 1993;100:660–662. 48. shaw Jc, white le. long-term safety of spironolactone in acne: results of an 8-year followup study. J Cutan Med Surg. 2002;6:541–545. 49. Plovanich m, weng Qy, mostaghimi a. low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151:941–944. 50. mackenzie is, morant sc, wei l, et al. spironolactone use and risk of incident cancers: a retrospectice, matched cohort study. Br J Clin Pharmacol. 2017;83:653–663. 51. Biggar rJ, andersen ew, wolhfahrt J, melbye m. spironolactone use and the risk of breast and gynaecologic cancers. Cancer Epidemiol. 2013;37:870–875. 52. mackenzie is, macdonald tm, thompson a, et al. spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ. 2012;345:e4447. 53. Heemers Hv, tindall dJ. androgen receptor (ar) coregulators: a diversity of functions converging on and regulating the ar transcriptional complex. Endocr Rev. 2007;28:778–808. 54. speros l, decherney a. evaluation of a new generation of oral contraceptives. Obstet Gynecol. 1993;81:1034–1047. 55. van vloten wa, van Haselen cw, van Zuuren eJ, et al. the esect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69:2–15. 56. raudrant d, rabe t. Progestogens with antiandrogenic properties. Drugs. 2003;63:463–492. 57. katz Hi, kempers s, akin md, et al. esect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care. 2000;5:248–255. 58. Prilepskaya vn, serov vn, Zharov ev, et al. esects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne. Contraception. 2003;68:239–245. 59. koulianos gt. treatment of acne with oral contraceptives: criteria for pill selection. Cutis. 2000;66:281–286. 60. shah ar. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol. 2008;7(9):847–850. 61. li ZJ, Park sB, sohn kc, et al. regulation of lipid production by acetylcholine signaling in human sebaceous glands. J Dermatol Sci. 2013;72:116–122. 62. rose ae, goldberg dJ. safety and etcacty of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013;39:443–448. 63. kurzen H, Berger H, Jager c, et al. Phenotypical and molecular proUling of the extraneuronal cholinergic system of the skin. J Invest Dermatol. 2004;123:937–949. 64. kurzen H, schallreuter kU. novel aspects in cutaneous biology of acetylcholine synthesis and acetylcholine receptors. Exp Dermatol. 2004;13:27– 30. 65. ibbotson sH. topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than nonmelanoma skin cancer. Br J Dermatol. 2002;146:178–188. 66. kosaka s, kawana s, Zouboulis cc, et al. targeting of sebocytes by aminolevulinic acid-dependent photosensitization. Photochem Photobiol. 2006;82:453–457. 67. Pollock B, turner d, stringer mr, et al. topical aminolaevulinic acid photodynamic therapy for the treatment of acne vulgaris: a study of clinical etcacy and mechanism. Br J Dermatol. 2004;51:616–622. 68. Horfelt c, stenquist B, larko O, et al. Photodynamic therapy for acne vulgaris: a pilot study of the dose- response and mechanism of action. Acta Derm Venereol. 2007;87:325–329. 69. Hongcharu w, taylor cr, chang y, et al. topical ala- photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol. 2000;115:183–192. 70. Perez-maldonado a, runger tm, krejci-Papa n. the 1,450-nm diode laser reduces sebum production in facial skin: a possible mode of action of its esectiveness for the treatment of acne vulgaris. Lasers Surg Med. 2007;39:189–192. 71. yeung ck, shek sy, yu cs, et al. treatment of invammatory facial acne with 1,450-nm diode laser in type iv to v asian skin using an optimal combination of laser parameters. Dermatol Surg. 2009;35:593–600. 72. laubach HJ, astner s, watanabe k, et al. esects of a 1,450 nm diode laser on facial sebum excretion. Lasers Surg Med. 2009;41:110–115. JCAD

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - AUG 2017